Fluorescein-guided surgery for the resection of pilocytic astrocytomas: A multicentric retrospective study

Jacopo Falco1, Julius Höhne2, Morgan Broggi1, Emanuele Rubiu1, Francesco Restelli1, Ignazio G. Vetrano1, Marco Schiariti1, Elio Mazzapicchi1, Giulio Bonomo1, Paolo Ferroli1, Karl-Michael Schebesch2 and Francesco Acerbi1*

1Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 2Department of Neurosurgery, Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany

Objective: Pilocytic astrocytomas (PAs) are relatively benign tumors, usually enhancing on post-contrast MRI and often characterized by a mural nodule within a cystic component. Surgical resection represents the mainstay of treatment, and extent of resection (EOR) is associated with improved survival. In this study, we analyzed the effect of sodium fluorescein (SF) on the visualization and resection of these circumscribed astrocytic gliomas.

Methods: Surgical databases at two neurosurgical departments (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy and Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany) were retrospectively reviewed to identify the cohort of patients with pilocytic astrocytoma who had undergone fluorescein-guided tumor resection at any of the centers between March 2016 and February 2022. SF was intravenously injected (5 mg/kg) immediately after the induction of general anesthesia. Tumors were removed using a microsurgical technique with the YELLOW 560 filter (Carl Zeiss Meditec, Oberkochen, Germany).

Results: Forty-four patients (25 males and 19 females; 26 pediatric patients, mean age of 9.77 years, range 2 to 17 years; and 18 adult patients, mean age of 34.39 years, range 18 to 58 years) underwent fluorescein-guided surgery. No side effects related to SF occurred. In all tumors, contrast enhancement on preoperative MRI was correlated with intense, heterogeneous yellow fluorescence with bright fluorescent cystic fluid. Fluorescein was considered helpful in distinguishing tumors from viable tissue in all cases except three patients due to faint fluorescein enhancement. Biopsy was intended in two operations, and partial resection was intended in three operations. Gross total resection was achieved in 24 cases out of 39 patients scheduled for tumor removal (61.54%), in five cases a minimal residual volume was highlighted by postoperative MRI despite the intraoperative subjective evaluation of complete...
tumor removal (12.82%); in the other 10 cases, the resection was subtotal with fluorescent residual spots to avoid neurological worsening (25.64%).

**Conclusions:** The use of SF is a valuable method for safe fluorescence-guided tumor resection. Our data showed a positive effect of fluorescein-guided surgery on intraoperative visualization during resection of PAs, suggesting a possible role in improving the extent of resection of these lesions.

**KEYWORDS**
pilocytic astrocytoma, central nervous system tumors, sodium fluorescein, neuro- oncology, YELLOW 560 filter, fluorescence-guided neurosurgery

**Introduction**

Pilocytic astrocytomas (PAs) are tumors that are often described as slow-growing lesions (1–3) with an indolent course. These astrocytic lesions present a peculiar epidemiological distribution as they are considered the most common glioma subtype among children, with a peak incidence in the first two decades of life, presenting a significantly lower occurrence in adults (4, 5). According to the 2016 (6) and 2021 (7) World Health Organization (WHO) tumor classification, pilocytic astrocytomas are classified as grade I and grade 1 tumors, respectively, and they are associated with an excellent prognosis, with a 10-year survival rate of more than 95% (8, 9). Notwithstanding the favorable clinical course of most PAs, a small subset of tumors is associated with rapid recurrence, especially for high proliferative tumor cells and unfavorable mutations (8, 10).

Those PAs present at MRI with well-circumscribed margins usually have both solid (predominant) and cystic components, with inhomogeneous contrast enhancement due to blood–brain barrier (BBB) disruption (1, 11).

The curative potential of surgical resection (2, 9, 12) is extremely affected by the location of the lesion and the difficulty, during intraoperative visualization, in discriminating the tumor margins; in particular, the hypothalamus or optochiasmatic region involvement can affect the prognosis; indeed, for these tumors, surgical resectability can sometimes be impossible; therefore, a chemotherapy approach is advisable after biopsy or debulking surgery. In this perspective, the application of new technical tools aimed at improving the extent of resection (EOR) could be beneficial. Patients are usually followed up by regular imaging as re-resection is advised at recurrence (12). Because of its long-term benign course, radiation therapy is generally considered in selected cases (8); palliative care with chemotherapy, radiation therapy, or both is an option for unresectable and multiple recurrent tumors (13).

Sodium fluorescein (SF) is a dye that, when intravenously injected, has the peculiar characteristic of accumulation in cerebral areas, presenting damage to the BBB (14, 15). The use of a dedicated filter in the surgical microscope, with a specific wavelength for fluorescein (540–690 nm), allows one to improve the tumor–brain discrimination intraoperatively, reducing the dosage needed to obtain this effect (16–18). In particular, this has been shown to be associated with better tumor identification and resection in different tumors of the central nervous system (CNS), such as high-grade gliomas (19, 20), gangliogliomas (21), cerebral metastasis (22), and primary CNS lymphomas (23), both in adult and pediatric populations (24).

In July 2015, based on preliminary scientific results from different studies published in the international literature (25, 26), including a prospective phase II trial from our group, the Italian Medicine Agency (AIFA) has extended the indications for the usage of fluorescein molecule (https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario;jsessionid=izVcTonmjOzRjw5ek AA:_ntc-as2-guri2h@atto.dataPubblicazioneGazzetta=2015-07-22&atto.codiceRedazionale=15A05620&elenco30giorni=false). According to this determination, the intravenous (i.v.) injection of SF as a neurosurgical tracer during oncological procedures for aggressive tumors of the CNS is approved and its cost is totally reimbursed by the Italian National Health System (20). In particular, a low dose (5 mg/kg) of fluorescein is i.v. administered at the end of patient intubation (around 1 h before dural opening); patients of any age and gender can be operated by means of SF according to this standardized protocol according to AIFA determination.

Due to the characteristics of MRI contrast uptake in PAs, the use of SF as a fluorescent tracer could allow better intraoperative discrimination of the tumoral tissue even in this tumor subtype, with beneficial effects during surgical resection (4). The foundation of our study rests upon the intrinsic staining potential of fluorescein and the radiological features of PAs, characterized by an intense contrast-enhanced pattern. The
rational is the usage of fluorescein molecule to selectively stain the contrast-enhanced areas of PAs to improve the intraoperative visualization of the solid portion of the tumor. In the presented paper, we performed a retrospective multicentric analysis of the contribution of fluorescein-guided technique for the removal of PAs, aiming to show the advantages and valuable role of fluorescein in the visualization and resection of pilocytic astrocytomas.

### Methods

#### Patients and inclusion criteria

In this study, we systematically and retrospectively reviewed surgical and neuropathological databases at two neurosurgical departments (Fondazione IRCCS Istituto Neuroligico Carlo Besta, Milan, Italy and Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany) to identify the cohort of patients affected by pilocytic astrocytoma who had undergone fluorescein-guided tumor resection at any center between March 2016 and February 2022. Inclusion criteria were informed consent about the use of SF, histopathologically confirmed PAs according to 2016 or 2022 WHO CNS tumor classification, and no known allergy to fluorescein. The surgical databases of the two Institution, from which the patient data were retrieved, were approved by the respective Institutional Review Boards. Additionally, the cohort of patients operated at the Fondazione IRCCS Istituto Neuroligico Carlo Besta were enrolled in a prospective observational study on the use of SF for contrast enhancing resection of CNS tumors (20), the FLUOCERTUM study (FLUOrescein in CERebral TUMors), also approved by the Institutional Review Board.

#### Clinical and radiological management

Preoperative assessment included physical and neurological examination (Karnofsky Performance Status [KPS] (27) in adult patients and Lansky Play-Performance status [LPS] (28) in pediatric ones), laboratory test results, preoperative contrast-enhanced MRI for neuronavigation. In preoperative MRI, patients were categorized based on their preoperative contrast enhancement characteristics. To evaluate the EOR, a volumetric MRI was performed for each patient within 72 h after surgery; in particular, to calculate the residual pathological volume, the hyperintense alterations in volumetric basal T1 acquisitions were subtracted from the volume of hyperintense tissue in post-contrast volumetric T1 images, to avoid the incidental inclusion of blood or blood products (29). The EOR was calculated as a percentage of tumor resection based on early contrast-enhanced postoperative MRI; according to the entity of resection, we distinguished four main categories: gross total resection (GTR, EOR 100%), sub-total resection (STR, with an EOR of 90%–100%), partial resection (PR, 30%–90%), and biopsy. The postoperative clinical evaluation included a standard neurological examination as above, a laboratory test (kidney function), and the exclusion of the occurrence of any side effect related to fluorescein injection. Clinical and neuroradiological long-term follow-up were performed for the postoperative period as part of normal clinical practice, including a telephonic interview.

#### Surgical protocol

The standardized surgical protocol of the fluorescein-guided technique, as already described in previous papers (16, 17, 20, 25, 26), is based on i.v. SF (Monico S.p.A., Venice, Italy and Alcon Pharma, Freiburg im Breisgau, Germany) injection at a standard dose of 5mg/kg, using a central or peripheral venous line, immediately upon completion of the induction of general anesthesia. Surgery was performed with the aid of a surgical microscope equipped with an integrated fluorescent filter tailored to the excitation and emission wavelengths of sodium fluorescein (YELLOW 560—Pentro 900 and Kinevo; Carl Zeiss Meditec, Oberkochen, Germany). During resection, the microscope could be switched alternatively from fluorescent to white-light illumination; neuronavigation, intraoperative contrast-enhanced ultrasounds, or other tools could be used according to the preference of the surgeon. Intraoperative neurophysiological monitoring was used in tumors located adjacent to eloquent areas. The tumors were removed in an inside-out fashion until all fluorescent tissue was removed, as considered feasible by the surgeon.

#### Intraoperative fluorescence characteristics and side effects

Fluorescence intensity was graded by the surgeon as intense, inhomogeneous or homogeneous, moderate, slight or absent; surgeons were also asked to classify the use of SF per procedure as helpful, partially helpful, unhelpful or not essential to achieve surgical aims. Furthermore, medical reports were evaluated for any possible adverse effect or allergic reaction to fluorescein administration.

#### Statistical analysis

The sample was described by means of the usual descriptive statistics: mean, median, and standard deviation for continuous variables and proportions for categorical ones. PRISM software for the Macintosh was used for the statistical analysis.
Results

Patients population

We enrolled 44 patients (25 males and 19 females; 26 pediatric patients, mean age 9.77 years, range 2 to 17 years; and 18 adult patients, mean age 34.39 years, range 18 to 58 years) affected by pilocytic astrocytomas.

All the patients presented with variable contrast enhancement patterns in the preoperative MRI: PAs mostly showed a solid, highly enhancing component (the mural nodule) with a large cyst (Figure 1); furthermore, several other contrast enhancement patterns were observed, such as homogeneous and intense contrast uptake or peripheral, heterogeneous contrast enhancement with central cystic-necrotic areas (Figure 2).

Data on the clinical condition at admission, discharge, and follow-up and intraoperative findings were available for all patients (Table 1).

Intraoperative fluorescence characteristics and surgeon’s opinion

Homogeneously intense fluorescent staining was reported in 19/44 cases (43.18%) whereas an inhomogeneous and intense fluorescence enhancement was described in 10 patients (22.73%); a moderate fluorescence was detected in 13/44 cases (29.55%) while in only two patients (4.55%) pathological tissue appeared slightly fluorescent (Table 1). In eight multicystic tumors (18.18%), independently from the specific fluorescein enhancement, we observed a bright fluorescent cystic fluid (Figures 1, 2). Preoperative corticosteroid therapy did not affect fluorescence characteristics.

In all cases but three, intraoperative fluorescence was deemed helpful (93.18%) in achieving a complete resection using a better delineation of the borders of the tumor tissue from the healthy parenchyma as compared with the conventional microsurgical technique using white-light illumination. In two cases (4.55%), SF was considered partially helpful in identifying the tumor (Table 1):
in fact, in one patient the fluorescence enhancement appeared moderate with tenuous SF uptake at tumor borders (Pat.18) whereas in the other one, SF, whose enhancement was slight, was used along with intraoperative ultrasound to identify the biopsy target (Pat.6). Finally, in one patient (2.27%), the tumor was slightly fluorescent under a YELLOW 560 filter, so SF was judged unhelpful in facilitating tumor resection (Pat.32). Intraoperative fluorescence corresponded to preoperative MRI documented contrast enhancement.

No technical difficulties regarding the use of the microscope filter nor switching between white and yellow light were encountered during the surgical resections.

**Extent of resection**

GTR was achieved in 24 cases out of 39 patients scheduled for tumor removal (61.54%), in five cases a minimal residual volume was highlighted by postoperative MRI despite the intraoperative subjective evaluation, both under white-light and YELLOW 560 filter activation, of complete tumor removal (12.82%); furthermore, neuronavigation check at the end of the surgery did not reveal tumor remnants, probably due to the intrinsic limitation of this tool in cases of brain shift at the end of surgery. In the other 10 cases, the resection was subtotal with fluorescent residual spots to avoid neurological worsening (expected STR in 25.64%); three patients with rapidly worsening of clinical status were scheduled for a partial removal with debulking aim of large and hemorrhagic tumors to relieve functional structures (Table 1).

A young patient with an atypical spinal lesion was scheduled for open biopsy. The pathological spinal cord appeared enlarged and pale with a few, moderate fluorescent spots; with the aid of intraoperative neurological monitoring and contrast-enhanced ultrasound, these components were removed for histological analysis, which was diagnostic for pilocytic astrocytoma; the patient did not present any neurological sequelae. Finally, an open biopsy was performed for the left frontal tumor.

**Side effects and outcome**

No adverse drug reaction related to SF injection was reported in this cohort of patients; the only remarkable and
| Nr. | Age | Gender | DOS | Clinical presentation | KPS pre-op | Tumor location | Fluorescence intensity | Intraparenchymal effects | Surgeon’s opinion | Residual fluorescence (Y/N - explanation) | EOR (GTR, intended STR, unintended STR, PR-debulking, biopsy) | Histology | KPS post-op | FU (Timing) | FU (Radio logical) | FU (KPS/LPS) |
|-----|-----|--------|-----|-----------------------|------------|----------------|-----------------------|------------------------|------------------|------------------------------------------|------------------------------------------|------------|-------------|-------------|----------------|-------------|
| 1   | 6   | F      | 08/03/16 | headache, visual disturbance | 80 | hypothalamus, opticochiasmatic | moderate | no | helpful | N | unintended STR | pilocytic astrocytoma (WHO I) | 80 | 5.2020 | tumor recurrence (→ CHT) | 70 |
| 2   | 12  | M      | 12/09/16 | left motor hemisindrome | 60 | right thalamo-mesencephalic | moderate | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the basal ganglia and thalamus | intended STR | pilocytic astrocytoma (WHO I) | 70 | 3.2021 | stable tumor | 90 |
| 3   | 18  | M      | 22/12/16 | nausea and altered color perception | 90 | right temporo-mesial, left frontal | homogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 100 | 8.2021 | tumor free | 100 |
| 4   | 3   | F      | 10/03/17 | NF1; right hemisindrome | 80 | left basal ganglia | moderate | no | helpful | N | unintended STR | pilocytic astrocytoma (WHO I) | 90 | 1.2022 | stable tumor | 90 |
| 5   | 6   | F      | 16/03/17 | functional impairment right superior limb, repetitive movements right hand and dystonic posture, aphasia | 80 | left basal ganglia and lateral ventricle | moderate (bright cystic fluid) | no | helpful | N | unintended STR | pilocytic astrocytoma (WHO I) | 70 | 12.2019 | progression disease (→ ReSurgery—25) | 90 |
| 6   | 7   | M      | 28/03/17 | hypotrophy and hyposthenia right inferior limb | 70 | D10-L1 | slight | no | partially helpful | Y — biopsy | Biopsy | pilocytic astrocytoma (WHO I) | 70 | 10.2021 | stable tumor | 60 |
| 7   | 18  | M      | 23/03/18 | headache, dysphagia, ataxia | 60 | midbrain, pons, right cerebellar | heterogeneously intense | no | helpful | Y—incomplete resection of the fluorescent component: tenacious adhesions to cranial nerves and brainstem | intended STR | pilocytic astrocytoma (WHO I) | 60 | 2.2022 | progression disease (→ ReSurgery—44) | 50 |

(Continued)
| Nr. | Age | Gender | DOS | Clinical presentation | Tumor location | Fluorescence intensity | Intraprocedural effects | Surgeon’s opinion | Residual fluorescence (Y/N - explanation) | EOR (GTR, intended STR, unintended STR, PR-debulking, biopsy) | Histology | KPS/LPS | FU (Timing) | FU (Radiological) | FU (KPS/LPS) |
|-----|-----|--------|-----|----------------------|----------------|-----------------------|------------------------|------------------|------------------------------------------|-----------------------------------------------|-----------|---------|-------------|----------------|-------------|
| 8   | 14  | M      | 08/05/18 | headache             | left temporal   | homogeneously intense | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 100       | 1.2022  | tumor free | 100            |             |
| 9   | 57  | F      | 15/06/18 | cerebellar syndrome | posterior cranial fossa | heterogeneously intense | no                     | helpful          | Y – incomplete resection of the fluorescent component: infiltration of the right cerebellar peduncle | intended STR pilocytic astrocytoma (WHO I) | 70        | 10.2019 | progression disease (→ CHT/RT) | 80             |             |
| 10  | 44  | F      | 15/06/18 | seizure              | left frontal     | homogeneously intense | no                     | helpful          | Y – biopsy                  | Biopsy pilocytic astrocytoma (WHO I)           | 90        | 4.2020  | stable tumor | 90             |             |
| 11  | 17  | M      | 12/07/18 | seizure              | left parieto-occipital | homogeneously intense (bright cystic fluid) | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 90        | 1.2022  | tumor free | 100            |             |
| 12  | 20  | M      | 02/08/18 | convulsions, speech arrest | left temporo-insular | moderate               | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 90        | 4.2021  | tumor free | 100            |             |
| 13  | 56  | M      | 11/09/18 | nausea, vomiting     | IV ventricle      | moderate               | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 100       | 11.2021 | tumor free | 100            |             |
| 14  | 15  | M      | 13/09/18 | NF1                  | left lateral ventricle | homogeneously intense | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 100       | 12.2021 | tumor free | 100            |             |
| 15  | 2   | F      | 14/09/18 | vertigo, squint, vomiting | left cerebellar hemisphere | homogeneously intense | no                     | helpful          | N                                        | GTR pilocytic astrocytoma (WHO I)               | 100       | 5.2021  | tumor free | 100            |             |
| 16  | 11  | M      | 01/10/18 | triventricular hydrocephalus | pineal gland, dorsal midbrain | heterogeneously intense | no                     | helpful          | Y – incomplete resection of the fluorescent component: infiltration of the midbrain | intended STR pilocytic astrocytoma (WHO I) | 90        | 11.2021 | stable tumor | 100            |             |
| Nr. | Age | Gender | DOS | Clinical presentation | KPS/ LPS pre-op | Tumor location | Fluorescence intensity | Intra-op side effects | Surgeon’s opinion | Residual fluorescence (Y/N - explanation) | EOR (GTR, intended STR, unintended STR, PR-debulking, biopsy) | Histology | KPS/ LPS post-op | FU (Timing) | FU (Radiological) | FU (KPS/ LPS) |
|-----|-----|--------|-----|------------------------|-----------------|---------------|------------------------|----------------------|---------------------|---------------------------------|---------------------------------|-----------|-----------------|-------------|-----------------|-------------|
| 17  | 14  | M      | 08/10/18 | headache, nausea and sickness | 90 | right cerebellar | heterogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 6.2021 | tumor free | 100 |
| 18  | 18  | M      | 06/12/18 | seizure | 90 | right temporal | moderate | no | partial helpful | N | unintended STR | pilocytic astrocytoma (WHO I) | 90 | 3.2022 | stable tumor | 90 |
| 19  | 18  | M      | 13/12/18 | headache | 100 | right temporal | moderate | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 100 | 11.2020 | tumor free | 100 |
| 20  | 14  | F      | 24/01/19 | headache, ideomotor impairment | 60 | posterior cranial fossa | heterogeneously intense (bright cystic fluid) | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the IV ventricle | intended STR | pilocytic astrocytoma (WHO I) | 80 | 5.2021 | stable tumor | 90 |
| 21  | 11  | F      | 15/04/19 | vertigo, headache | 100 | IV ventricle | homogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 100 | 7.2019 | tumor free | 100 |
| 22  | 6   | F      | 07/06/19 | vertigo, visual deficits, vomiting | 80 | right cerebellar hemisphere | homogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 11.2021 | tumor free | 100 |
| 23  | 37  | F      | 27/09/19 | bilateral cervicodorsalgia | 70 | D2-D3 | moderate | no | helpful | Y—incomplete resection of the fluorescent component: infiltrative behavior with IONM positive response | intended STR | pilocytic astrocytoma (WHO I) | 50 | 3.2022 | stable tumor | 60 |
| 24  | 10  | M      | 20/11/19 | headache and diplopia | 90 | posterior cranial fossa | heterogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 70 | 2.2022 | tumor free | 80 |
| 25* | 9   | F      | 16/12/19 | FU pat.5 (functional impairment right superior limb, aphasia) | 90 | left temporal and lateral ventricle | homogeneously intense | no | helpful | Y—incomplete resection of the fluorescent component: | intended STR | pilocytic astrocytoma (WHO I) | 90 | 2.2022 | stable tumor | 90 |

(Continued)
| Nr. | Age | Gender | DOS | Clinical presentation | KPS/ LPS pre-op | Tumor location | Fluorescence intensity | Intra-op side effects | Surgeon’s opinion | Residual fluorescence (Y/N - explanation) | EOR (GTR, intended STR, un-intended STR, PR-debulking, biopsy) | Histology | KPS/ LPS post-op | FU (Timing) | FU (Radiological) | FU (KPS/ LPS) |
|-----|-----|--------|-----|----------------------|----------------|----------------|----------------------|---------------------|------------------|------------------------------------------|--------------------------------------------------------|------------|-----------------|------------|----------------|-------------|
| 26  | 21  | F      | 24/02/20 | diplopia, headache, postural instability | 80 | left cerebellar | homogeneously intense (bright cystic fluid) | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 80 | 9.2021 | tumor free | 90 |
| 27  | 13  | M      | 02/04/20 | seizure | 90 | right frontal | moderate | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 11.2021 | tumor free | 100 |
| 28  | 5   | M      | 26/06/20 | left hemiparesis, visual loss | 60 | hypothalamus, opticochiasmatic | heterogeneously intense | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the optic chiasm | PR-debulking | pilocytic astrocytoma (WHO I) | 60 | 1.2022 | stable tumor | 70 |
| 29  | 9   | M      | 04/08/20 | left VII c.n. deficit, ataxia | 70 | right thalamomesencephalic | moderate | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 80 | 10.2021 | tumor free | 90 |
| 30  | 49  | F      | 14/10/20 | headache | 70 | left hippocampal | homogeneously intense | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 70 | 6.2021 | tumor free | 70 |
| 31  | 6   | M      | 04/11/20 | optic neuropathy | 80 | hypothalamus, opticochiasmatic | homogeneously intense | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the optic chiasm | intended STR | pilocytic astrocytoma (WHO I) | 80 | 11.2021 | stable tumor | 80 |
| 32  | 54  | F      | 26/11/20 | NF1 | 90 | left frontal | slight | no | not helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 1.2022 | tumor free | 90 |
| 33  | 58  | M      | 09/02/21 | amnesia | 80 | III ventricle | moderate | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the hypothalamus | intended STR | pilocytic astrocytoma (WHO I) | 70 | 10.2021 | stable tumor | 80 |
| Nr. | Age | Gender | DOS | Clinical presentation | KPS/ LPS pre-op | Tumor location | Fluorescence intensity | Intra-op side effects | Surgeon’s opinion | Residual fluorescence (Y/N - explanation) | EOR (GTR, intended STR, unintended STR, PR-debulking, biopsy) | Histology | KPS/ LPS post-op | FU (Timing) | FU (Radiological) | FU (KPS/ LPS) |
|-----|-----|--------|-----|-----------------------|-----------------|----------------|-----------------------|-----------------------|-----------------|---------------------------------------------|-----------------------------------------------|-----------|-----------------|-------------|-----------------|-------------|
| 34  | 26  | F      | 26/02/ | radiological FU in pre-existing encephalitis disseminata | 100 | posterior callosal body, right lateral ventricle | homogeneously intense |  | no | helpful | N | unintended STR | pilocytic astrocytoma (WHO I) | 100 | 1.2022 | progression disease | 100 |
| 35  | 8   | M      | 04/06/ | headache, nausea and vomiting ideomotor impairment, right hemisoma weakness | 80 | cerebellar vermis | homogeneously intense |  | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 10.2021 | tumor free | 90 |
| 36  | 16  | M      | 15/06/ | headache, nausea and vomiting ideomotor impairment, right hemisoma weakness | 90 | left cerebellar peduncle | homogeneously intense (bright cystic fluid) |  | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 10.2021 | tumor free | 100 |
| 37  | 13  | M      | 13/09/ | nausea, vomiting ideomotor impairment, right hemisoma weakness | 70 | right temporal parietal | moderate |  | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 80 | 3.2022 | recurrent tumor | 100 |
| 38  | 15  | F      | 29/10/ | headache, right hemiparesis | 60 | left temporal | homogeneously intense |  | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 90 | 3.2022 | tumor free | 90 |
| 39  | 23  | M      | 13/12/ | nausea, ataxia, nystagmus | 80 | IV ventricle | heterogeneously intense (bright cystic fluid) |  | no | helpful | Y—incomplete resection of the fluorescent component: infiltration of the IV ventricle and right Luschka foramen | intended STR | pilocytic astrocytoma (WHO I) | 40 | \ | \ | \ |
| 40  | 53  | F      | 16/12/ | ptosis, double vision | 100 | right frontal temporal | homogeneously intense |  | no | helpful | N | GTR | pilocytic astrocytoma (WHO I) | 80 | 2.2022 | tumor free | 80 |
| 41  | 6   | M      | 12/01/ | left hemiparesis, hydrocephalus | 60 | hypothalamus, diencephalon | heterogeneously intense (bright cystic fluid) |  | no | helpful | Y—incomplete resection of the fluorescent component: tenacious adhesions to eloquent areas | PR-debulking | pilocytic astrocytoma (WHO I) | 60 | \ | \ | \ |

(Continued)
visible effect was the transient yellowish staining of urine, which disappeared in about 24 h.

At baseline, 30/44 (68.2%) of patients had KPS/LPS scores of 80–100, indicating good clinical and neurological conditions. Surgical morbidity led to a postoperative decline in KPS/LPS score in seven patients at discharge, but only in one case was the clinical worsening marked with a decrease of 40 points in the KPS/LPS score; 25 patients were discharged with an unchanged KPS/LPS score, whereas 12 patients presented with a clinical improvement using surgical treatment. At discharge, 31/44 (70.5%) of patients had KPS/LPS scores of 80–100 (Table 1).

Long-term follow-up data were available for 39 patients; all of them were alive during this time; the follow-up period ranged between 2 and 58 months, with a median follow-up of 26.4 months. Most patients (33/39—84.6%) were neuroradiologically stable (tumor free or stable remnant tumor); 15 patients presented a clinical improvement measured using the KPS/LPS score, 17 patients were unchanged and only one patient presented with a slight clinical worsening. Six patients presented with tumor recurrence or progression disease, but only two were clinically worsened; two of them were scheduled for re-do surgery, whereas the other two were for adjuvant radiotherapy and chemotherapy. Two patients are prosecuted for follow-up with a wait and see approach (Table 1).

Discussion

To our knowledge, this is the first report specifically evaluating the use of fluorescein-guided surgery in PA resection. Given that the contrast uptake in the preoperative T1-weighted MRI reflects the fluorescent staining pattern of the tumor (14, 20), we hypothesized that the use of the SF would have positively affected the intraoperative magnification of these neoplasms. Indeed, the use of SF could improve tumor visualization and, therefore, the entity of tumor removal (19); our observation was associated with contrast enhancement on preoperative MRI, which was present in almost all tumors in our series.

Thirty-nine patients enrolled in the study were scheduled for surgery with a previous planning of macroscopic resection but keeping in mind the philosophy of maximal safe resection: in this series, we obtained GTR in more than half of the patients (24/39, 61.54%); these data can be explained by the fact that many tumors were located in such eloquent regions in which a sub-total resection is sometimes advisable. As a matter of fact, minimal residual tumor (lower than 10% of preoperative tumor volume) at postoperative MRI was expected in 10 cases (25.64%), as it was involving eloquent areas or due to the adherence to major brain vessels or cranial nerves and was therefore independent of the fluorescence visualization. Conversely, in five cases (12.82%), the residual tumor was an
unprecedented finding, based on the absence of clear residual intraoperative fluorescent tissue; this can be related, as for other fluorophores, to the fact that the residual tissue was not exposed during resection because it was hidden under the normal brain parenchyma. In almost all cases, surgeon-reported visibility of pathological tissue was clearly enhanced by SF and YELLOW 560 filter views and was almost always judged helpful for complete tumor resection.

Pilocytic astrocytomas represent 1.6% of all CNS neoplasms and account for 5% of all glial tumors annually diagnosed in children and adults (1, 5, 8); approximately 60% of PAs are diagnosed in the pediatric population, representing about 17% of all intracranial tumors in children (30). They can arise anywhere along the neuroaxis, but they are usually found in deep midline structures such as the cerebellum, the opticochiasmatic region, and hypothalamus, the brainstem, and the spinal cord (4). In the pediatric population, the cerebellum is the most common site of presentation (2, 9). In contrast, no difference in tumor distribution was found in adults between the infratentorial and supratentorial compartments (8, 31).

According to the WHO CNS5 classification (7), pilocytic astrocytomas are considered circumscribed astrocytic gliomas in consideration of their more solid growth pattern, as opposed to the strongly infiltrative behavior of diffuse astrocytomas. Indeed, PAs usually present an overall indolent course in the pediatric population (2, 32); unfavorable prognostic factors negatively affecting the overall survival (OS) are the diencephalic region location, the pilomyxoid variant, the proliferation index, or the adherence and infiltration of the thick cystic wall to the brain, prejudicing surgical radicality (11). Aggressive surgical resection continues to be one of the most important prognostic factors (32, 33) because of its irrefutable correlation with both overall survival and progression-free survival (PFS).

According to recent published data by different international groups (10, 34–38), GTR was achievable in about half of the patients operated with white-light illumination (53.81%). In this perspective, the application of new technical tools aimed at improving the EOR could be beneficial in the management of PAs. During the last few years SF has emerged as an intraoperative fluorescent tracer with tumors that uptake contrast (26), along with the inclusion of both primary and recurrent PAs, no proper patient evaluation from a prognostic perspective was possible. Moreover, we did not make any comparison between the use of SF and white-light illumination or other available fluorophores, like 5-ALA. Despite these weaknesses, our study could represent a proof of concept that may indicate that fluorescence use is potentially useful in the identification of tumoral tissue and in achieving a high rate of GTR of PAs. Optimal dosage and timing of SF in PA surgery is neither known nor experienced in this study. Also, in this cohort of tumors, we have used a low dosage of 5 mg/kg, intravenously injected at the time of patient intubation (16), as originally proposed by our group in January 2012 (25).

The main limitation of the presented study is represented by the lack of data about OS, given the prolonged survival of PAs, a long-term follow-up is not available in our data; for this reason, along with the inclusion of both primary and recurrent PAs, no proper patient evaluation from a prognostic perspective was possible. Moreover, we did not make any comparison between the use of SF and white-light illumination or other available fluorophores, like 5-ALA. Despite these weaknesses, our study could represent a proof of concept that may indicate that fluorescence use is potentially useful in the identification of tumoral tissue and in achieving a high rate of GTR of PAs. As previously demonstrated with other lesions, further studies could better elucidate the contribution of fluorescence-guided technique in improving the intraoperative visualization during surgical
resection of this tumor subtype. Furthermore, the effect of fluorescein on PFS and OS needs to be evaluated in a randomized, controlled clinical trial with adequate power to precisely assess the outcomes within a predefined observation period.

Conclusion

Our data suggest a positive effect of fluorescein-guided surgery during resection of PAs with contrast enhancement on preoperative MRI. We assert that SF is a safe and feasible tool; the use of fluorescein and a YELLOW 560 filter is a readily available method for fluorescence-guided tumor resection, allowing intraoperative tumor visualization similarly to contrast enhancement in brain MRI.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethical Committees of the Fondazione IRCCS Istituto Neurologico Carlo Besta and of the University Medical Center Regensburg. Written informed consent to participate in this study as well as for the publication of any potentially identifiable images or data included in this article was obtained from the individual(s), and minor(s)’ legal guardian/next of kin.

References

1. Berger MS, Weller M. Pilocytic astrocytomas. *Glia*. (2016) doi: 10.1002/ b978-0-12-802997-8.00020-7
2. Doddshun AJ, Maxnner WJ, Hansford JR, Sullivan MJ. Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. *J Neurosurg Pediatrics* (2016) 17:569–72. doi: 10.3171/2015.9.PEDS15449
3. Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: Analysis of the surveillance, epidemiology, and end results program of the national cancer institute. *J Neurooncol* (2012) 108(1):187–93. doi: 10.1007/s00401-011-1410-7
4. Collins VP, Jones DTW, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. *Acta Neuropathol* (2015) 129(6):775–88. doi: 10.1007/s00401-015-1410-7
5. Ostrom QT, Patel N, Ciolfi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2013-2017. *Neuro Oncol* (2020) 22(12 Suppl 2): iv1–iv96. doi: 10.1093/neuonc/noaa200
6. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* (2016) 131(6):803–20. doi: 10.1007/s00401-016-1545-1
7. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol* (2021) 23(8):1231–51. doi: 10.1093/neo/napa106
8. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB. Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. *J Neurooncol* (2009) 95(3):377–382. doi: 10.1007/s11060-008-9935-z
9. Colin C, Padovani L, Chappé C, Mercurio S, Scavarda D, Loundou A, et al. Outcome analysis of childhood pilocytic astrocytomias: A retrospective study of 148 cases at a single institution. *Neuropath Appl Neurobiol* (2013) 39(6):693–705. doi: 10.1111/nan.12013
10. Mair MJ, Wohrer A, Furtner J, Simonovska A, Kiesel B, Oberndorfer S, et al. Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. *J Neurooncol* (2020) 148(1):187–98. doi: 10.1007/s11060-020-03513-9
11. Wade A, Hayhurst C, Amato-Watkins A, Lammie A, Leach P. Cerebellar pilocytic astrocytoma in adults: A management paradigm for a rare tumour. *Acta Neurochir (Wien)* (2013) 155(8):1431–5. doi: 10.1007/s00701-013-1790-1

Author contributions

JF and FA: study concept and design. JF, JH, K-MS, and FA: critical revision of the manuscript for intellectual content. All authors: acquisition of data, data analysis and interpretation. K-MS, PF and FA: study supervision. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This study was partially supported by the Associazione Paolo Zorzi per le Neuroscienze, ONLUS and by the Italian Ministry of Health (RRC).

Conflict of interest

FA, JH, and K-MS received honoraria from the Carl Zeiss Meditec Company for lectures at International Congresses.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be constructed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Falco et al. 10.3389/fonc.2022.943085

12. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for neuro- oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendrogliod glomas. Lancet Oncol (2017) 18(6):e315–29. doi:10.1016/S1470-2045(17)30194-8

13. Parsons MW, Whipple NS, Poppe MM, Mender JS, Cannon DM, Burt LM. The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. J Neurooncol (2021) 151(2):93–103. doi:10.1007/s10937-020-01365-y

14. Diaz RJ, Dios RR, Hattab EM, Cannon DM, Burt LM. MRI and operated with a dedicated multicentric prospective phase II study (FLUOGLIO). Fluorescein-guided removal of peripheral nerve sheath tumors: A preliminary report.

15. Moore GE. Fluorescein as an agent in the differentiation of normal and malignant tissues. Science (1947) 80(1):130–1. doi:10.1126/science.107.2674.130-a

16. Acerbi F, Broggi M, Broggi G, Ferroli P. What is the best timing for fluorescein injection during surgical removal of high-grade gliomas? Acta Neurochir (Wien) (2015) 157(8):1377–8. doi:10.1007/s00701-015-2455-z

17. Cavallo C, De Laurentis C, Vetrano IG, Falco J, Broggi M, Schiariti M, et al. The utilization of fluorescein in brain tumor surgery: A systematic review. J Neurosurg (2016) 121(6):1360–9. doi:10.3171/2015.1.JNS132507

18. Vetrano IG, Acerbi F, Falco J, Devigli G, Rinaldo S, Messina G, et al. Fluorescein-guided removal of peripheral nerve sheath tumors: A preliminary analysis of 20 cases. J Neurosurg (2021) 1–6.10. doi:10.3171/2019.9.JNS19070

19. Acerbi F, Broggi M, Schebesch KM, Höhne J, Cavalle C, De Laurentis C, et al. Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLO). Clin Cancer Res (2018) 24(13):32–6. doi:10.1158/1078-0432.CCR-17-1184

20. Falco J, Cavalle C, Vetrano IG, de Laurentis C, Sirolos L, Schiariti M, et al. Fluorescein application in cranial and spinal tumors enhancing at preoperative MRI and operated with a dedicated filter on the surgical microscope: Preliminary results in 279 patients enrolled in the FLUOCERTUM prospective study. Front Surg (2019) 6:49. doi:10.3389/fugs.2019.00049

21. Höhne J, Acerbi F, Falco J, Açakaya MO, Schmidt NO, Kiris T, et al. Lighting up the tumor–fluorescein-guided resection of gangliogliomas. J Clin Med (2020) 9(8):2405. doi:10.3390/jcm9082405

22. Schebesch KM, Hoehe J, Hohenberger C, Proescholdt M, Riemenschneider MJ, Wendt C, et al. Fluorescein sodium-guided resection of cerebral metastases—experience with the first 30 patients. Acta Neurochir (Wien) (2015) 157(6):899–904. doi:10.1007/s00701-015-2395-7

23. Schebesch KM, Hoehe J, Hohenberger C, Acerbi F, Broggi M, Proescholdt M, et al. Fluorescein sodium–guided surgery in cerebral lymphoma. Clin Neuroradiol (2015) 155(7):1277–86. doi:10.1007/s00701-015-1734-9

24. de Laurentis C, Höhne J, Cavalle C, Restelli F, Falco J, Broggi M, et al. The impact of fluorescein–guided technique in the surgical removal of CNS tumors in a pediatric population: Results from a multicentric observational study. J Neurosurg Sci (2019) 63:679–87. doi:10.2336/s0390-5616.19.06001-0

25. Acerbi F, Broggi M, Eotti M, Anghileri E, Cappini L, Pollo B, et al. Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: Preliminary results in 12 cases. Acta Neurochir (Wien) (2013) 155(7):1277–86. doi:10.1007/s00701-013-1734-9

26. Acerbi F, Cavallo C, Schebesch KM, Açakaya MO, de Laurentis C, Hamanns-Muk MK, et al. Fluorescein-guided resection of pediatric spinal cord tumors: Results from a preliminary, multicentric, retrospective study. World Neurosurg (2017) 108:603–9. doi:10.1016/j.wneuro.2017.09.061

27. Mor V, Laliberte I, NW, Wiesmann M. The karnofsky performance status scale. Cancer (1984) 53(9):2002–7. doi:10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530063.CO;2-J

28. Lansky SB, Lust MA, Landry LI, Ritter-Street C, Miller DR. The measurement of performance in childhood cancer patients. Cancer (1987) 60(7):1651–6. doi:10.1002/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J

29. Grabowski MM, Recinos P, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg (2014) 121(5):1115–23. doi:10.3171/2014.7.JNS132449

30. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 109(1):93–108. doi:10.1007/s00401-005-0991-y

31. Theeler RJ, Ellemar R, Sadighi ZS, Mehta V, Tran MD, Adesina AM, et al. Adult pilocytic astrocytomas: Clinical features and molecular analysis. Neuro Oncol (2014) 16(6):841–7. doi:10.1093/neuonc/not246

32. Tibbetts KM, Ennett RJ, Gao F, Perry A, Gutmann DH, Leonard JR. Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol (2009) 117(6):657–65. doi:10.1007/s00401-009-0509-3

33. Sadighi Z, Slopis I. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity. J Child Neurol (2013) 28(5):625–32. doi:10.1177/0883081412478347

34. Bhatt H, Bhatti MI, Patel C, Leach P. Paediatric posterior fossa tumour resection rates in a small volume centre: the past decade’s experience. Br J Neurosurg (2015) 31(4):451–5. doi:10.1017/btn.2015.977

35. Nelson AJ, Zakaria R, Jenkinson MD, Brodbelt AR. Extent of resection predicts risk of progression in adult pilocytic astrocytoma. Br J Neurosurg (2019) 33(3):343–7. doi:10.1017/btn.2018.1349315

36. Jungk C, Reinhardt A, Warta R, Cramer D, von Deimling A, Herold-Mende C, et al. Extent of resection, MGMT promoter methylation status and tumor location independently predict progression-free survival in adult sporadic pilocytic astrocytoma. Cancers (Basel) (2019) 11(8):1072. doi:10.3390/cancers11081072

37. Boschetti G, Santos AJ, Fermon KP, de Freitas Honório GL, Batistella G, Kusma SZ, et al. Adult pilocytic astrocytomas: A Brazilian series. World Neurosurg (2020) 133:e115–20. doi:10.1016/j.wneu.2019.08.146

38. Bond KM, Hughes ID, Porter AL, Ortna J, Fang S, Parney IF. Adult pilocytic astrocytoma: An institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg (2018) 110:276–83. doi:10.1016/j.wneuro.2017.11.102

39. Höhne J, Schebesch KM, de Laurentis C, Açakaya MO, Pedersen CB, Bravanesku A, et al. Fluorescein sodium in the surgical treatment of recurrent glioblastoma multiforme. World Neurosurg (2019) 123:e158–64. doi:10.1016/j.wneuro.2019.01.042

40. Schweke M, Schipmann S, Mütter M, Köchling M, Brentrup A, Stummer W. S-ALA fluorescence-guided surgery in pediatric brain tumors—a systematic review. Acta Neurochir (Wien) (2019) 161(6):1099–108. doi:10.1007/s00701-019-03898-1